 |
200 Diseases |  |
192 Trials |
|
192 Trials |  |
21013 News |  |
| «12...165166167168169170171172173174175...221222» |
- || Lamprene (clofazimine) / Novartis, Humira (adalimumab) / Eisai, AbbVie
Review, Journal: Medication-Induced Repigmentation of Gray Hair: A Systematic Review. (Pubmed Central) - Feb 6, 2020
There is also low-quality evidence that some vitamin B complex supplementation can promote gray hair darkening. While these compounds are not currently indicated for the treatment of gray hair, their mechanisms shed light on targets for future medications for hair repigmentation.
- | Remicade (infliximab) / J&J, NN1213 / Novo Nordisk, Humira (adalimumab) / AbbVie
Trial completion date: SUSI-CS: Stavanger IBD Study - Cross Sectional (clinicaltrials.gov) - Feb 5, 2020
P=N/A, N=210, Active, not recruiting, Sponsor: Helse Stavanger HF
While these compounds are not currently indicated for the treatment of gray hair, their mechanisms shed light on targets for future medications for hair repigmentation. Trial completion date: Nov 2020 --> Dec 2021
- ||||| Humira (adalimumab) / AbbVie
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis (clinicaltrials.gov) - Feb 5, 2020
P3, N=59, Active, not recruiting, Sponsor: AbbVie
Trial completion date: Nov 2020 --> Dec 2021 Enrolling by invitation --> Active, not recruiting | N=93 --> 59 | Trial completion date: Mar 2026 --> May 2025 | Trial primary completion date: May 2023 --> Mar 2025
- || Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date, HEOR: Rheumatoid Arthritis Satisfaction Outcome Research (clinicaltrials.gov) - Feb 5, 2020
P=N/A, N=840, Recruiting, Sponsor: Pfizer
Enrolling by invitation --> Active, not recruiting | N=93 --> 59 | Trial completion date: Mar 2026 --> May 2025 | Trial primary completion date: May 2023 --> Mar 2025 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- | Humira (adalimumab) / AbbVie
New P4 trial, Head-to-Head: ADDORA-switch: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (clinicaltrials.gov) - Feb 4, 2020
P4, N=84, Recruiting, Sponsor: Reade Rheumatology Research Institute
- | Orencia (abatacept) / BMS
New P4 trial: Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) (clinicaltrials.gov) - Feb 4, 2020
P4, N=60, Not yet recruiting, Sponsor: St George's, University of London
- | Humira (adalimumab) / Eisai, AbbVie
Humira is $28,999 for six weeks @abbvie (Twitter) - Feb 4, 2020
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical: 1/Has the patient had an MRE. 2/ is the TI normal. 3/ is it 1ry or 2d failure to Humira. The answers to the above ?? Would make my decision easier. Risk stratification puts her on high risk considering young age, perinatal disease. Tofa is this case would not be my 1st choice. (Twitter) - Feb 4, 2020
- || Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
Would continue tofacitinib. Would antibodies to adalimumab make a difference? Possible role for IFX in future with Aza if immunogenic failure? (Twitter) - Feb 3, 2020
- Humira (adalimumab) / Eisai, AbbVie
Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis () - Feb 3, 2020 - Abstract #AAN2020AAN_4949;
We describe 3 cases of persistent neurocysticercosis-associated inflammation that highlight both the efficacy and complications of SSAs use in neurocysticercosis. Our series emphasizes the need for further study on the use of SSAs in the treatment of neurocysticercosis-related inflammation.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Niemann-Pick disease type C presenting as very early onset inflammatory bowel disease. (Pubmed Central) - Feb 1, 2020
He did not have any typical neurological symptoms at the time of his diagnosis. He is currently doing well on biweekly adalimumab injections for his Crohn's disease and biweekly intrathecal injections of 2-hydroxypropyl-β-cyclodextrin (VTS-270) for the NPC.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
Actually not sure if the V-plex measures IL-6 bound to soluble receptors. We also see no effect of tocilizumab (but clear effect of adalimumab) preventing the pembro induced activation. I will show you at EULAR hopefully 😊 (Twitter) - Feb 1, 2020
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region. (Pubmed Central) - Jan 31, 2020
The risk of TB with TNF inhibitor was higher than with a non-TNF biologic (hazard ratio 4.34; 95% CI 1.31-14.39), while the risk of infliximab was higher than etanercept and adalimumab (hazard ratio: 4.10 and 2.08, respectively). The risk of TB is much higher in patients with immune-mediated diseases on biological therapy compared with the general population, and infliximab is associated with the highest risk of TB among the biologics analysed.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. (Pubmed Central) - Jan 31, 2020
The risk of TB is much higher in patients with immune-mediated diseases on biological therapy compared with the general population, and infliximab is associated with the highest risk of TB among the biologics analysed. This multicentre, retrospective cohort study reflecting real-life clinical practice provides the first evidence that proactive TDM of adalimumab may be associated with a lower risk of treatment failure compared with standard of care in patients with IBD.
- | Journal: Inflammatory bowel disease and targeted oral anti-TNFα therapy. (Pubmed Central) - Jan 31, 2020
Several oral anti-TNFα agents have been investigated with success but are not yet in general clinical use. This partially reflects the fact that the oral administration of antibodies has many barriers including the harsh environment of the GI tract and the presence of enzymes including pepsin, trypsin and chymotrypsin in the intestine which provide significant challenges to targeted oral therapy.
- ||| Clinical: Clarification: We stopped all 4 previous meds (Humira, azathioprine, allopurinol and mesalamine) and switched to tofacitinib (Xeljanz). A year later he maintains remission (clinical and endoscopic) on 1 drug instead of 4 (Twitter) - Jan 31, 2020
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Pulmonary aspergillosis in a Crohn's disease patient receiving adalimumab and steroid therapy. (Pubmed Central) - Jan 30, 2020
This partially reflects the fact that the oral administration of antibodies has many barriers including the harsh environment of the GI tract and the presence of enzymes including pepsin, trypsin and chymotrypsin in the intestine which provide significant challenges to targeted oral therapy. No abstract available
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Regional Variations in the Use of Biologics and Immunomodulators among Korean Patients with Inflammatory Bowel Diseases. (Pubmed Central) - Jan 30, 2020
No abstract available Regional variation exists in medication prescription rates within a single city as well as nationwide, suggesting that standardization of IBD treatment is necessary in Korea.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease. (Pubmed Central) - Jan 30, 2020
Worries included having an ostomy bag, undergoing surgery, developing cancer: conditions significantly associated with worsened disease activity and low treatment adherence. Higher treatment adherence scores/greater workability improvements were observed in patients treated with anti-TNF-α agents.
- ||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Journal, Adverse events: Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. (Pubmed Central) - Jan 30, 2020
P=N/A
This study enables the identification of 118 drugs associated with DIL. The list of suspected drugs may prove useful to physicians when confronted with potential DIL cases.
- | Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
Journal, HEOR: Tofacitinib in the treatment of moderate to severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. (Pubmed Central) - Jan 30, 2020
The list of suspected drugs may prove useful to physicians when confronted with potential DIL cases. From a payer perspective, second-line treatment with tofacitinib plus MTX is a cost-effective treatment strategy, compared with adalimumab plus MTX, in patients with moderate to severe RA in Taiwan.
- | Xeljanz (tofacitinib) / Pfizer, Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Journal: Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. (Pubmed Central) - Jan 30, 2020
From a payer perspective, second-line treatment with tofacitinib plus MTX is a cost-effective treatment strategy, compared with adalimumab plus MTX, in patients with moderate to severe RA in Taiwan. In RA patients with an inadequate response to cs- or b-DMARDs, upadacitinib 15 mg + MTX and upadacitinib 30 mg + MTX were the most efficacious interventions and were not associated with significant risks of serious adverse events.
- || Clinical, Review, Journal: SYSTEMIC REVIEW OF EOSINOPHILIC DERMATOSES PATIENTS TREATED WITH TNF-Α INHIBITORS AND USTEKINUMAB (Pubmed Central) - Jan 30, 2020
These drugs may act as triggers among Wells' syndrome patients. Further investigation is needed.
- |||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical: 6. HLA-C*06:02 negative psoriasis patients with PsA are 6X more likely to respond to #adalimumab compared to #ustekinumab 7. IL36RN, AP1S3 and CARD14 mutations are associated with pustular psoriasis. (Twitter) - Jan 30, 2020
- ||| Humira (adalimumab) / Eisai, AbbVie
Daughter has crohns and is taking humira also has mitral valve issues so this is very frightening to me. (Twitter) - Jan 30, 2020
- || Humira (adalimumab) / Eisai, AbbVie
Might that explain five approved adalimumab biosims being shelved until ~2023 ? (Twitter) - Jan 29, 2020
- || Humira (adalimumab) / Eisai, AbbVie
Yes. And extended patent protection for originator biologics, i.e., Humira/abbvie (Twitter) - Jan 29, 2020
- ||| Humira (adalimumab) / Eisai, AbbVie, Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Pricing, Reimbursement, HEOR: Insurances pay for millions $ in Humira because they are convinced of the cost-effectiveness and of the QALY increase. How come we fail to convince them to pay $10,000 for a single-course of Avycaz to save a life? (Twitter) - Jan 29, 2020
- | Decadron (dexamethasone) / Merck (MSD), Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab every other week combined with dexamethasone pulses for the treatment of refractory hidradenitis suppurativa. (Pubmed Central) - Jan 28, 2020
Further investigation is needed. No abstract available
- || Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Biologics exposure during pregnancy and breastfeeding in a psoriasis patient. (Pubmed Central) - Jan 28, 2020
There are few data available on biologics treatment safety during pregnancy and breastfeeding, especially regarding ustekinumab. We report our positive experience with the aim of increasing case notifications, facilitate meta-analysis and eventual consensus recommendations regarding the use of biologics in special population.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab (Pubmed Central) - Jan 28, 2020
We report our positive experience with the aim of increasing case notifications, facilitate meta-analysis and eventual consensus recommendations regarding the use of biologics in special population. No abstract available
- || Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
22 yo M law student on IFX since 2013, slow progression fibrostenosing ileal CD. Post-op ICR x 1 mo. BC refuses Humira, wants me to rx Entyvio or Cimzia first. WTF? WhyTryandFail?? (Twitter) - Jan 28, 2020
- |||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
#Ustekinumab lowers aortic vascular inflammation, #Adalimumab and #Phototherapy lower IL-6, a key inflammatory maker of CV risk, #Phototherapy improves cholesterol profile. None of these treatments influence #glucose metabolism (Twitter) - Jan 28, 2020
- | Humira (adalimumab) / Eisai, AbbVie
Preclinical, Journal: Efficacy of adalimumab therapy in experimental rat sclerosing encapsulated peritonitis model. (Pubmed Central) - Jan 28, 2020
No abstract available Adalimumab can prevent SEP development.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
HIGHER ANTI-TNFα TROUGH LEVELS ARE ASSOCIATED WITH INCREASED RADIOLOGICAL RESPONSE IN PERIANAL FISTULISING CROHN'S DISEASE: A MULTI-CENTRE STUDY () - Jan 28, 2020 - Abstract #DDW2020DDW_3546;
Radiological response, defined based on Van Assche inflammatory sub-scores derived from MRI pelvis, was associated with a significantly higher level of anti-TNFα drug level. Larger data sets are required to further characterise anti-TNFα drug level targets in pfCD.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY () - Jan 28, 2020 - Abstract #DDW2020DDW_3318;
P3
Higher maintenance treatment with 40 EW was generally safe and well tolerated with a similar safety profile to 40 EOW. No new long-term safety concerns were observed.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
VEDOLIZUMAB - PERIOPERATIVE INFECTION RATES IN PATIENTS WITH IBD () - Jan 28, 2020 - Abstract #DDW2020DDW_3134;
Our findings suggested that VDZ is safe to use during the perioperative period and it does not increase perioperative risk of infection. We recommend further investigations with prospective study and larger population coverage to solidify our findings.
- Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
TREATMENT PERSISTENCE AND MAINTENANCE DOSING FOR USTEKINUMAB AND ADALIMUMAB AMONG PATIENTS WITH CROHN’S DISEASE WITH TWO-YEARS FOLLOW-UP IN THE SYMPHONY HEALTH DATABASE () - Jan 28, 2020 - Abstract #DDW2020DDW_3130;
Persistence for adalimumab was 60% at 1 year, with 74% of those persistent patients still on therapy at 2 years. Dosages that are 50% or greater than the US PI recommendations were more common with adalimumab.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
TRANSMURAL HEALING IN PATIENTS WITH CROHN’S DISEASE TREATED WITH ANTI-TNF THERAPY () - Jan 28, 2020 - Abstract #DDW2020DDW_3129;
Conclusion Transmural healing, which is associated with better outcomes in CD, can be achieved in more than half of patients with CD. The best time to assess transmural healing was between 6 to 8 months after starting anti-TNF therapy.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
HIGH RATE OF LOSS OF RESPONSE POST DE-ESCALATION DESPITE PROLONGED EXPOSURE TO COMBINATION THERAPY () - Jan 28, 2020 - Abstract #DDW2020DDW_3120;
Adequate serum concentration of the TNF inhibitor prior to deescalation was not protective against LOR. Any decision to de-escalate must be carefully considered and patients advised of the possible consequences
- EVALUATION OF BIOLOGIC TREATMENT PATTERNS AMONG CROHN’S DISEASE PATIENTS USING THREE LARGE UNITED STATES CLAIMS DATABASES () - Jan 28, 2020 - Abstract #DDW2020DDW_3119;
Introduction: Real-world evidence on treatment patterns among Crohn’s disease (CD) patients using biologics remains limited, particularly among ustekinumab (UST) patients...Patients (aged 18-64 years) were required to have ≥1 claim for CD and ≥1 claim for biologics (UST, vedolizumab [VDZ], infliximab [IFX], certolizumab pegol [CZP], or adalimumab [ADA]) during the identification period (IQVIA: 09/26/16-12/31/17; MarketScan: 09/26/16-09/30/17; Optum: 09/26/16-03/31/18)... Among CD patients, unadjusted persistence was numerically higher in the UST cohort with consistent trends in the bio-naïve and bio-experienced subsets.
- ASSESSMENT OF BODY WEIGHT CHANGES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES INITIATING BIOLOGIC THERAPY: A PROSPECTIVE COHORT STUDY () - Jan 28, 2020 - Abstract #DDW2020DDW_3106;
Neither clinical response to therapy nor disease activity parameters showed any statistical association with weight gain. Conclusion There was no difference in weight gain among the different biologic therapeutic classes.
- IBD IS ASSOCIATED WITH INCREASED RISK OF ACUTE PANCREATITIS: A POPULATION BASED ANALYSIS () - Jan 28, 2020 - Abstract #DDW2020DDW_3038;
CD patients had a higher rate of AP when compared to UC patients. The treatment of IBD with anti-inflammatory medications or biologic agents reduced the rate of AP in IBD patients, likely resulting from indirect treatment of an autoimmune etiology to AP.
- INFLAMMATORY BOWEL DISEASE AND LUNG CANCER: RISK AND ROLE OF IBD THERAPY () - Jan 28, 2020 - Abstract #DDW2020DDW_3012;
Patients receiving treatment for IBD are at lower risk to develop lung cancer especially on biological agents. This may be due to higher clinical remission and inflammation control in patients receiving treatment.
- DISEASE BURDEN AND OUTCOMES OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH HIV INFECTION IN THE UNITED STATES: A POPULATION BASED STUDY () - Jan 28, 2020 - Abstract #DDW2020DDW_3005;
This specific population needs more care given their worse disease outcomes and higher medical burden. More studies are needed to further delineate the clinical association and effect of HIV therapy on disease outcome.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
ANTI-TUMOR NECROSIS FACTOR THERAPY AND EOSINOPHILIC ESOPHAGITIS: IS THERE A CONNECTION? () - Jan 28, 2020 - Abstract #DDW2020DDW_2933;
The initiation of an anti-TNF in patients with IMD was associated with an increased occurrence of EoE in our population. The underlying pathophysiologic mechanism of this increased risk of anti-TNF therapy requires further investigation.
- THE NATURAL HISTORY OF COLECTOMY AMONG HOSPITALIZED PATIENTS WITH ULCERATIVE COLITIS IN THE CONTEMPORARY ERA OF BIOLOGICS () - Jan 28, 2020 - Abstract #DDW2020DDW_2681;
Stabilization in the colectomy rate may suggest a finite efficacy with the current approach for managing acute severe UC. Thoughtful new approaches for identifying and preventing colectomy in the remaining high-risk patients are needed.
- PATIENT REPORTED OUTCOMES: THE ICHOM STANDARD SET FOR IBD IN REAL LIFE PRACTICE HELPS QUANTIFY DEFICITS IN CURRENT CARE () - Jan 28, 2020 - Abstract #DDW2020DDW_2670;
(adalimumab 13%, golimumab <1%, infliximab 9%, tofacitinib 1%, ustekinumab 1%, vedolizumab 16%)...Conclusion Outcomes reported by patients illustrate the scale of the therapeutic deficit in current care. The ICHOM Standard Set acts as a benchmark for comparing outcomes between institutions
- INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNOBIOLOGIC THERAPY ARE LESS LIKELY TO DEVELOP COLORECTAL CANCER: ANALYSIS OF THE EXPLORYS DATABASE () - Jan 28, 2020 - Abstract #DDW2020DDW_2664;
In this large database, IBD patients who were treated with immunobiologics were less likely to develop CRC. Further studies are required to determine if immunobiogics are chemoprotective by inflammation control and mucosal healing.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic University, Humira (adalimumab) / Eisai, AbbVie
THE ESCALATION OF THERAPY OR INTERVENTION (ETI) CALCULATOR FOR ULCERATIVE COLITIS - DOES IT HAVE THE POTENTIAL TO HELP OUTPATIENT CAPACITY MEET DEMAND? () - Jan 28, 2020 - Abstract #DDW2020DDW_2630;
Conclusion A model that predicts the likelihood of treatment escalation or intervention during an OPA, based on real time data entered by patients, has the potential to improve outpatient clinic resource utilisation. The calculator may not be valid to triage patients recently on steroids.